Medical Xpress

DECEMBER 6, 2022

But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive.

Drugs 63

Drugs Licensing Licensing Branding 63

XTalks

MAY 5, 2022

The Paleo certification comes at a time when the global market for Paleo foods is projected to reach $12.6 In the US alone, the Paleo market was estimated at $2.7 billion in 2020, with cereals, bakery products and snacks being some of the largest market segments.

Packaging 98

Packaging Packaging Licensing Licensing 98

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. On signing of the deal, AbbVie will make an upfront payment of $40m to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

MAY 30, 2023

Alkindi is one of EffRx’s three marketed drugs. The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland.

Contract Manufacturing 130

Contract Manufacturing Clinical Supply Licensing Licensing 130

The Pharma Data

NOVEMBER 4, 2020

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8

Licensing 40

Licensing Licensing Dermatology Production 40

XTalks

MAY 22, 2023

Conscious Greens is the first offering from Pairwise’s new brand, Conscious Foods. Pairwise teamed up with Performance Food Group (PFG) to co-brand its Purple Power Baby Greens Blend under PFG’s Peak Fresh Produce premium brand. Paul region, St. Louis and Springfield, Massachusetts.

Branding 98

Branding Gene Editing DNA Production 98

Pharmaceutical Technology

MAY 31, 2023

Its pipeline product also comprises Xepol XP-28 which is used for the treatment of post-polio syndrome and is under pre-license sales among others. It markets products under the brand TARPEYO. Calliditas Therapeutics also partners with medical research institutions such as the Karolinska Institute and Uppsala University.

Clinical Trials 100

Clinical Trials Clinical Trials Production Licensing 100

Fossil Remedies

NOVEMBER 22, 2022

If you are a budding entrepreneur who wants to launch a business of your own, then opening a pharmaceutical marketing firm could be a better choice. The prerequisites to becoming successful in a pharma franchise business are your predictability and supervision of the market. Selection of brand. Wide range of products.

Branding 52

Branding Pharma Production Production Marketing 52

XTalks

JULY 10, 2023

This transaction is pending approval from the bankruptcy court and the Federal Trade Commission (FTC), which is currently reviewing the potential sale; however, if given the green light, this deal could potentially be beneficial for both brands. That year, Red Bull led the market with $6.8 billion and Bang earning a respectable $1.3

Branding 98

Branding Sales Containment Licensing 98

XTalks

SEPTEMBER 16, 2020

While it may seem counterintuitive, the strategy involves making “growth investments” including a 30 percent increase in marketing spending. Heinz and Kraft Foods in 2015, costs were cut by $2 billion, but the combined company fought to grow sales of its long-running food brands in an era of changing tastes.

Branding 98

Branding Sales Manufacturing Licensing 98

XTalks

JANUARY 12, 2021

. “At International Delight, we are always looking to give our fans innovative, can’t-get-it-anywhere-else flavors to enhance their coffee,” said Marie Dobson, marketing director for International Delight, in a statement. Companies recognize this feeling and build on it in brand advertising and product development.

Branding 98

Branding Production Marketing Development 98

XTalks

SEPTEMBER 22, 2023

Recent initial public offerings (IPOs) from food companies such as Cava Group and BranchOut Food might give the impression of a reawakening IPO market after a seemingly quiet year. billion valuation after a successful market introduction on June 15. This shift nudged Instacart’s market capitalization to approximately $11.1

Branding 64

Branding Marketing Licensing Licensing 64

pharmaphorum

FEBRUARY 11, 2022

Ipsen’s consumer health range includes brands like diarrhoea remedy Smecta, Forlax for constipation and Ginkgo biloba supplement Tanakan, which recorded revenues of €226 million in 2021, up 8%. billion takeover of Clementia Pharma in 2019. billion of its revenues last year.

Sales 103

Sales Pharma Companies Branding Cosmetics 103

XTalks

JUNE 23, 2021

We’re thrilled to collaborate with Cinnabon to give families a new way to enjoy the flavor of a Cinnabon cinnamon roll, while still offering all of the protein, vitamins and minerals that families love about Carnation Breakfast Essentials,” said Abigail Buckwalter, vice president of marketing at Nestlé Health Science USA, in a statement.

Branding 52

Branding Protein Licensing Licensing 52

pharmaphorum

JULY 14, 2022

It has a history of buying up mature brands from other pharma companies, for example paying $300 million for rights to AstraZeneca’s migraine therapy Zomig (zolmitriptan) in a similar deal five years ago. Grünenthal will make the purchase in cash upfront, with the final figure dependent on any closing adjustments.

Drugs 97

Drugs Sales Pharma Companies Cardiology 97

pharmaphorum

JANUARY 8, 2021

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is already in the late stages of development and expected to be approved in Europe later this year.

Licensing 52

Licensing Licensing Pharma Companies Branding 52

Pharma Marketing Network

SEPTEMBER 22, 2021

Listen to how pharmaceutical brands and clinicians are adapting to this new modality and are pivoting their promotional efforts to ensure that they can leverage the Telehealth channel effectively. Panelists: Tim Glennon , Vice President of Marketing, Evofem Biosciences. Tres Garcia , Director Marketing, Agile Chapter Lead, Merck.

Big Data 52

Big Data Marketing Life Science Licensing 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. We’re doing this all the time – constantly taking new products into the markets that we’re familiar with. The rate of drug approvals could be on the rise.

Drugs 130

Drugs Pharma Companies Sales Production 130

pharmaphorum

JANUARY 20, 2022

The Swiss subsidiary of Glenmark Pharmaceuticals and Lotus International have signed a licensing agreement whereby Glenmark will handle the manufacture and supply of Ryaltris and Lotus will take charge of commercialising the drug, subject to approval.

Allergies 72

Allergies Marketing Manufacturing Production 72

pharmaphorum

JANUARY 23, 2023

Chinese biotech Hutchmed’s push to sign partnerships for its drug products outside its home market has resulted in a $1.13 Fruquintinib has already been approved in China – under the Elunate brand name – becoming the country’s first home-grown therapy for a major form of cancer back in 2018.

Licensing 52

Licensing Licensing Sales Marketing 52

Druggist

DECEMBER 28, 2020

The Government recently announced the reclassification of fexofenadine 120mg, which will be available as General sale Medication (GSL), sold as branded products – Allevia 120mg tablets. Once Allevia reaches the market, I will update this post accordingly. fexofenadine hydrochloride 120g tablets (generic and branded as Telfast).

Pharmacy 98

Pharmacy Doctors Doctor Allergies 98

pharmaphorum

FEBRUARY 1, 2021

Kesimpta (ofatumumab) started life as an oncology drug and was first developed by Genmab and licensed to GlaxoSmithKline who marketed under the brand name Arzerra to treat chronic lymphocytic leukaemia. The post CHMP clears way for EU approval of Novartis’ MS drug appeared first on.

Drugs 98

Drugs Hormones FDA Approval Licensing 98

pharmaphorum

OCTOBER 26, 2022

German specialty drugmaker Neuraxpharm has licensed commercial rights in Europe to a wearable device developed by Spanish start-up mjn-neuro that is designed to warn a person with epilepsy about an impending seizure. “By entering the digital health market, Neuraxpharm can provide further assistance and tap this unmet potential.”

Licensing 64

Licensing Licensing Branding Production 64

pharmaphorum

MARCH 31, 2021

Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . Novartis licenses the drug from Genmab and reformulated into its Sensoready autoinjector pen. Analysts say Kesimpta could make $1.3

Licensing 98

Licensing Licensing Sales Gene Therapy 98

pharmaphorum

FEBRUARY 12, 2021

The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.

Drugs 111

Drugs Sales Pharma Companies Marketing 111

Pharmacy Checkers

JANUARY 10, 2020

A friend of mine, who has very difficult to control cholesterol, was prescribed Livalo, an FDA-approved brand of the drug pitavastatin. He went to our site to discover that brand-name Livalo ( pitavastatin ). He went to our site to discover that brand-name Livalo ( pitavastatin ). Let’s call him John. Is the drug safe?

FDA Approval 62

FDA Approval Branding Pharmacy Manufacturing 62

Pharma Marketing Network

SEPTEMBER 22, 2021

Listen to how pharmaceutical brands and clinicians are adapting to this new modality and are pivoting their promotional efforts to ensure that they can leverage the Telehealth channel effectively. Panelists: Tim Glennon , Vice President of Marketing, Evofem Biosciences. Tres Garcia , Director Marketing, Agile Chapter Lead, Merck.

Big Data 40

Big Data Marketing Life Science Licensing 40

Fossil Remedies

OCTOBER 23, 2019

You can market drugs under your brand name. The last and final step is to verify the license requirements. Establish your brand in the market. Once the company is launched, it is time to promote the brand by using every possible channel. Do the research well and invest in marketing and advertising.

Manufacturing 67

Manufacturing Branding Pharma Companies Pharma Production 67

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Licensing 40

Licensing Licensing Production Development 40

Pharmaceutical Technology

NOVEMBER 9, 2022

Known by the brand name Roctavian, BioMarin’s haemophilia A therapy valoctocogene roxaparvovec could be fairly priced in the range of $1.95–1.96 CSL Behring has a commercialisation and license agreement to develop EtranaDez. million, the think tank concluded in its updated evaluation. million ($1.5 million ($1.8

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

pharmaphorum

MARCH 16, 2022

Viatris’ generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been cleared for the same indications as the brand, namely maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD).

FDA Approval 59

FDA Approval Generic Drugs Marketing Drug Delivery 59

pharmaphorum

JULY 26, 2022

Regulators in the US and Europe have started to review Novartis’ biosimilar version of Biogen’s big-selling multiple sclerosis therapy Tysabri, which could reach the market next year. There was also continued decline for Tecfidera, which have not been offset by follow-up Vumerity (diroximel fumarate), which has fewer side effects.

Sales 52

Sales Marketing Drugs Licensing 52

pharmaphorum

APRIL 6, 2022

The EU regulator has started a review of Novartis’ PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the drug due in July. The Swiss pharma giant licensed ex-China rights to tislelizumab from BeiGene in February 2021 for $650 million upfront and up to $1.55

Drugs 52

Drugs Licensing Licensing FDA Approval 52

pharmaphorum

APRIL 20, 2021

However, she reckons it will still trail Roche’s first-to-market anti-CD20 drug Ocrevus (ocrelizumab), even though that drug needs to be administered by intravenous infusion. billion by 2028. While it requires a clinic visit, Ocrevus only has to be administered twice a year. billion in sales in 2028.

Sales 111

Sales Medicine Drugs Marketing 111

Druggist

DECEMBER 31, 2020

Vibegron (brand name: Gemtesa) is the latest drug used to treat overactive bladder that has been approved by the FDA in the USA. Licensed use and legal status of vibegron (US). Vibegron – licensed use and legal status. 3-adrenoreceptor agonist licensed for the management of overactive bladder. How does Vibegron work? .

Drugs 59

Drugs Licensing Licensing Clinical Trials 59

pharmaphorum

SEPTEMBER 23, 2022

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis’ rival therapy Leqvio. ” The big pharma is said to be considering the future of the programme. billion in sales by 2027, ahead of Repatha at $2.2

Drugs 59

Drugs Licensing Licensing Sales 59

pharmaphorum

OCTOBER 12, 2022

The provision of these records must be readily available for auditing, and failing such regulatory audits can ultimately result in a license withdrawal. Both of these can ultimately deteriorate brand reputation. On top of this, if cyber-attacks are frequent, partners and consumers can become mistrusting. About the author.

Compliance 105

Compliance Manufacturing Life Science Production 105